FDA transparency reforms: publishing complete response letters

By Dr Nicola Davies

The pharmaceutical industry is experiencing a seismic shift in regulatory transparency as the US Food and Drug Administration (FDA) implements its most ambitious disclosure initiative to date.

In September 2025, the agency announced that it will begin releasing complete response letters (CRLs) in real-time, fundamentally altering how drug approval processes are communicated to the public.¹ This unprecedented move represents what FDA Commissioner Dr Marty Makary has termed "radical transparency," but the implications for drug developers, public trust, and the approval ecosystem are far more complex than the terminology suggests.